Key Takeaways
- • IM8 secures $1 billion in non-dilutive funding from General Catalyst's Customer Value Fund (CVF), structured as a revenue-based loan rather than equity investment, preserving founder and existing shareholder ownership stakes.
- • CVF loan finances up to 70% of customer acquisition costs with General Catalyst receiving a capped percentage of reference income (revenue multiplied by fixed gross-margin assumption) until capital recovery and revenue cap are achieved, after which all subsequent customer revenue flows to Prenetics.
- • IM8 demonstrates exceptional growth trajectory, reaching $180 million in annual recurring revenue (ARR) within 16 months of launch—among the fastest-growing supplement brands on record—validating the revenue-based financing model for high-velocity consumer businesses.
- • Danny Yeung leads IM8 as CEO, having previously founded Prenetics (which went public in 2022); IM8 operates as a Prenetics subsidiary selling subscription-based vitamin drinks formulated with longevity-linked compounds including açai fruit extract and Coenzyme Q10.
- • CVF emerges as alternative capital vehicle for profitable, subscription-based businesses, following Grammarly's $1 billion CVF draw in May 2025, demonstrating General Catalyst's larger $8 billion healthcare and consumer-focused capital allocation strategy announced in 2026.
Summary
David Beckham's health drink startup IM8 closed a $1 billion funding round from General Catalyst's Customer Value Fund on July 14, 2026, marking a significant capital deployment in the rapid-growth supplement sector. Unlike traditional venture equity rounds, the CVF structure preserves IM8's ownership composition by providing capital through revenue-based financing rather than equity dilution. This approach aligns with General Catalyst's broader healthcare investment thesis, part of an $8 billion fund allocation announced for healthcare-focused companies in 2026.
The loan is engineered specifically for consumer businesses with predictable revenue streams and subscription models. General Catalyst will finance up to 70% of IM8's customer acquisition costs and receive a capped percentage of what it terms "reference income"—defined as revenue generated from those customers multiplied by a fixed gross-margin assumption. Upon recovery of its capital and achievement of the revenue cap, General Catalyst's claim terminates, and all subsequent revenue from those customers accrues to Prenetics, IM8's parent company.
IM8's growth metrics underscore the strength of its business model: the brand achieved $180 million in annual recurring revenue within 16 months of launch, positioning it among the fastest-growing supplement brands on record. CEO and co-founder Danny Yeung, a self-described high school dropout, previously founded Prenetics, which completed a public listing in 2022. IM8 operates as a Prenetics subsidiary, selling subscription-based vitamin drinks formulated with compounds linked to longevity, including açai fruit extract and Coenzyme Q10. According to available reports, the brand reached $10 million in monthly revenue during its growth phase.
The CVF structure has gained traction with high-growth consumer technology platforms. Grammarly similarly drew $1 billion from CVF in May 2025 prior to acquiring Superhuman, validating General Catalyst's thesis that revenue-based financing serves as a capital-efficient alternative for founders seeking growth capital without equity dilution. For institutional investors evaluating alternative financing mechanisms, the IM8 round demonstrates how venture capital firms are adapting structures to match the cash-flow characteristics of mature, subscription-driven consumer businesses.
The loan is engineered specifically for consumer businesses with predictable revenue streams and subscription models. General Catalyst will finance up to 70% of IM8's customer acquisition costs and receive a capped percentage of what it terms "reference income"—defined as revenue generated from those customers multiplied by a fixed gross-margin assumption. Upon recovery of its capital and achievement of the revenue cap, General Catalyst's claim terminates, and all subsequent revenue from those customers accrues to Prenetics, IM8's parent company.
IM8's growth metrics underscore the strength of its business model: the brand achieved $180 million in annual recurring revenue within 16 months of launch, positioning it among the fastest-growing supplement brands on record. CEO and co-founder Danny Yeung, a self-described high school dropout, previously founded Prenetics, which completed a public listing in 2022. IM8 operates as a Prenetics subsidiary, selling subscription-based vitamin drinks formulated with compounds linked to longevity, including açai fruit extract and Coenzyme Q10. According to available reports, the brand reached $10 million in monthly revenue during its growth phase.
The CVF structure has gained traction with high-growth consumer technology platforms. Grammarly similarly drew $1 billion from CVF in May 2025 prior to acquiring Superhuman, validating General Catalyst's thesis that revenue-based financing serves as a capital-efficient alternative for founders seeking growth capital without equity dilution. For institutional investors evaluating alternative financing mechanisms, the IM8 round demonstrates how venture capital firms are adapting structures to match the cash-flow characteristics of mature, subscription-driven consumer businesses.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.